Renal risk stratification with the new oral anticoagulants (JULY 2013) TO THE EDITOR: I read with interest the review of the new oral anticoagulants by Fawole et al 1 and agree with their comments on the prevention of bleeding and the importance of monitoring renal function in managing patients on the new classes of oral anticoagulants. However, no specifics were given on how to proceed. Thus, I recommend that renal risk stratification be done before and 1 week after starting these new drugs.
Originally, the US Food and Drug Administration approved dabigatran (Pradaxa) at a dose of 150 mg orally twice daily in patients with a creatinine clearance of 15 to 30 mL/min/1.73 m 2 . This dosing corresponded to the estimated glomerular filtration rate (eGFR) in patients with stage 4 chronic kidney disease, but this dosing is contraindicated in other guidelines worldwide (Canada, Europe, the United Kingdom, Japan, Australia, and New Zealand).
2 Not unexpectedly, 3,781 serious adverse effects were noted in the 2011 US postmarketing experience with dabigatran. These included death (542 cases), hemorrhage (2,367 cases), acute renal failure (291 cases), stroke (644 cases), and suspected liver failure (15 cases).
3
Thirteen months after dabigatran's approval in the United States, Boehringer Ingelheim changed the dosage and product guidelines.
2-4
The new dosage 4 is 75 mg twice daily for patients with a creatinine clearance of 15 to 30 mL/min/1.73 m 2 . Therefore, I suggest a nephrologic "way out" 5 when using the new oral anticoagulants to avoid the problems with dabigatran noted above.
First, if these drugs are to be used in nonvalvular atrial fibrillation, risk factors should be determined using the CHADS2 or the CHADS2-VASc score. Special attention should be given to patients age 75 and older, women, and patients with a history of stroke, transient ischemic attack, or systemic embolism. All of these have been noted to be major risk factors. This simple renal risk stratification guideline should help avoid some of the problems noted in the dabigatran postmarketing experience, which were aggravated by the lack of approval of a 110-mg dose and by misleading advertising, claiming that no blood monitoring was required.
2-5 Thus, the new oral anticoagulants should be a welcome addi- 
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IN REPLY:
We agree with the comments of Dr. Pazmiño regarding specifics of renal risk stratification in patients taking the new oral anticoagulants. In order to reduce the bleeding risks associated with these agents, they should be prescribed on the basis of the individual patient's clinical characteristics. We did not discuss this since the focus of our article was management of bleeding that resulted from use of these drugs. We appreciate the recommendations of Dr. Pazmiño.
